Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice-Reference-Cited by-同舟云学术

Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice

Published:2012-10-10 Issue:2 Volume:139 Page:269-280
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Angelucci Domenico,Tinari Nicola,Grassadonia Antonino,Cianchetti Ettore,Ausili-Cefaro Giampiero,Iezzi Laura,Zilli Marinella,Grossi Simona,Ursini Lucia Anna,Scognamiglio Maria Teresa,Castrilli Graziella,De Tursi Michele,Noccioli Paolo,Cioffi Pasquale,Iacobelli Stefano,Natoli Clara

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00432-012-1325-9

Reference54 articles.

1. Alm El-Din MA, Taghian AG (2009) Breast conservation therapy for patients with locally advanced breast cancer. Semin Radiat Oncol 19(4):229–235. doi: 10.1016/j.semradonc.2009.05.005

2. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L (2012) Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 9(1):16–32. doi: 10.1038/nrclinonc.2011.177

3. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21(22):4165–4174. doi: 10.1200/jco.2003.12.005

4. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24(13):2019–2027. doi: 10.1200/jco.2005.04.1665

5. Berruti A, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou C, Daidone M, Conte P, Kennedy D, Damia G, Petronini P, Di Cosimo S, Bruzzi P, Dowsett M, Desmedt C, Mansel RE, Olivetti L, Tondini C, Sapino A, Fenaroli P, Tortora G, Thorne H, Bertolini F, Ferrozzi F, Danova M, Tagliabue E, de Azambuja E, Makris A, Tampellini M, Dontu G, Van’t Veer L, Harris AL, Fox SB, Dogliotti L, Bottini A (2011) International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr 43:147–151. doi: 10.1093/jncimonographs/lgr037

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A historical controlled study of domestic trastuzumab and pertuzumab in combination with docetaxel for the neoadjuvant treatment of early HER2-positive breast cancer;Frontiers in Oncology;2024-02-09

2. Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting;Cells;2021-07-03

3. Neoadjuvant docetaxel with or without carboplatin plus dual HER2 blockade for HER2-positive breast cancer: a retrospective multi-center Chinese study;Gland Surgery;2020-12

4. Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Carcinoma: A Real-World Study;BioMed Research International;2020-05-05

5. Is Multifocal Regression a Risk Factor for Ipsilateral Breast Tumor Recurrence in the Modern Era After Neoadjuvant Chemotherapy and Breast Conservation Therapy?;International Journal of Radiation Oncology*Biology*Physics;2019-07